Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
08:40am, Sunday, 30'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders
07:23am, Sunday, 30'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia T
NEW YORK, NY / ACCESS Newswire / March 29, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 202
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
09:00am, Saturday, 29'th Mar 2025
NEW YORK , March 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and J
NTLA Investors Have Opportunity to Lead Intellia Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
08:36am, Saturday, 29'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options NEW YORK,
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
06:30pm, Friday, 28'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30,
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Suc
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia T
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
06:24am, Friday, 28'th Mar 2025
Intellia received RMAT designation from the FDA of nex-z for the treatment of patients with Transthyretin [ATTR] Amyloidosis with Cardiomyopathy. Global sales of the Transthyretin Amyloidosis market i
